Suspicions regarding the genetic inheritance of acute lymphoblastic leukemia in patients with down syndrome

1Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193-203. doi: 10.1038/nrc1816.Greaves M Infection, immune responses and the aetiology of childhood leukaemia Nat Rev Cancer 20066 3 193 203 10.1038/nrc1816Open DOISearch in Google Scholar

2Icabucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975-83. doi: 10.1200/JCO.2016.70.7836.Icabucci I Mullighan CG Genetic basis of acute lymphoblastic leukemia J Clin Oncol 201735 9 975 83 10.1200/JCO.2016.70.7836Open DOISearch in Google Scholar

3Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76:747–56. doi: 10.1002/bdra.20294.Canfield MA Honein MA Yuskiv N Xing J Mai CT Collins JS et al National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001 Birth Defects Res A Clin Mol Teratol 200676747 56 10.1002/bdra.20294Open DOISearch in Google Scholar

4Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165–9. doi: 10.1016/S0140-6736(99)05264-2.Hasle H Clemmensen IH Mikkelsen M Risks of leukaemia and solid tumours in individuals with Down’s syndrome Lancet 2000355165 9 10.1016/S0140-6736(99)05264-2Open DOISearch in Google Scholar

5Hasle H, Clemmensen IH, Mikkelsen M. Incidence of cancer in individuals with Down syndrome. Tidsskr Nor Laegeforen. 2000;120:2878–81.Hasle H Clemmensen IH Mikkelsen M Incidence of cancer in individuals with Down syndrome Tidsskr Nor Laegeforen 20001202878 81Search in Google Scholar

6Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7. doi: 10.1182/blood-2013-06-509463.Buitenkamp TD Izraeli S Zimmermann M Forestier E Heerema NA van den Heuvel-Eibrink MM et al Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group Blood 201412370 7 10.1182/blood-2013-06-509463Open DOISearch in Google Scholar

7Harigae H. GATA transcription factors and hematological diseases. Tohoku J Exp Med. 2006;210:1–9. doi: 10.1620/tjem.210.1.Harigae H GATA transcription factors and hematological diseases Tohoku J Exp Med 20062101 9 10.1620/tjem.210.1Open DOISearch in Google Scholar

8Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia. 2016;30:1816–23. doi: 10.1038/leu.2016.164.Lee P Bhansali R Izraeli S Hijiya N Crispino JD The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome Leukemia 2016301816 23 10.1038/leu.2016.164Open DOISearch in Google Scholar

9Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, et al. Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia. 2012;26(10):2204-11. doi: 10.1038/leu.2012.84.Buitenkamp TD Pieters R Gallimore NE van der Veer A Meijerink JP Beverloo HB et al Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations Leukemia 201226 10 2204 11 10.1038/leu.2012.84Open DOISearch in Google Scholar

10Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83. doi: 10.1182/blood-2007-09-114231.Forestier E Izraeli S Beverloo B Haas O Pession A Michalová K et al Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study Blood 2008111 3 1575 83 10.1182/blood-2007-09-114231Open DOISearch in Google Scholar

11Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood. 2010;116(7):1045-50. doi: 10.1182/blood-2009-07-235291.Maloney KW Carroll WL Carroll AJ Devidas M Borowitz MJ Martin PL et al Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group Blood 2010116 7 1045 50 10.1182/blood-2009-07-235291Open DOISearch in Google Scholar

12Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-46. doi: 10.1038/ng.469.Mullighan CG Collins-Underwood JR Phillips LA Loudin MG Liu W Zhang J et al Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia Nat Genet 200941 11 1243 46 10.1038/ng.469Open DOISearch in Google Scholar

13Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014;46(6):618–23. doi: 10.1038/ng.2949.Lane AA Chapuy B Lin CY Tivey T Li H Townsend EC et al Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation Nat Genet 201446 6 618 23 10.1038/ng.2949Open DOISearch in Google Scholar

14Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, et al. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med. 2015;212(6):953–70. doi: 10.1084/jem.20150002.Thompson BJ Bhansali R Diebold L Cook DE Stolzenburg L Casagrande AS et al DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3 J Exp Med 2015212 6 953 70 10.1084/jem.20150002Open DOISearch in Google Scholar

15Tirado CA, Shabsovich D, Kim Y, et al. A case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements. Biomark Res. 2015;3:11. doi: 10.1186/s40364-015-0036-1. eCollection 2015.Tirado CA Shabsovich D Kim Y et al A case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements Biomark Res 2015311 10.1186/s40364-015-0036-1. eCollection 2015Open DOISearch in Google Scholar

16Hertzberg L, Vendramini E, Ganmore I, Traum P, Pullarkat S, Kallen M, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006–17. doi: 10.1182/blood-2009-08-235408.Hertzberg L Vendramini E Ganmore I Traum P Pullarkat S Kallen M et al Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group Blood 2010115 5 1006 17 10.1182/blood-2009-08-235408Open DOISearch in Google Scholar

17Rampal R, Levine RL. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Bailliere's Best Practice in Clinical Haematology. 2014;27(2):83–93. doi: 10.1016/j.beha.2014.07.001.Rampal R Levine RL A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms Bailliere's Best Practice in Clinical Haematology 201427 2 83 93 10.1016/j.beha.2014.07.001Open DOISearch in Google Scholar

18Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood. 2007;109(5):2202–4. doi: 10.1182/blood-2006-09-045963.Malinge S Ben-Abdelali R Settegrana C Radford-Weiss I Debre M Beldjord K et al Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia Blood 2007109 5 2202 4 10.1182/blood-2006-09-045963Open DOISearch in Google Scholar

19Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484–92. doi: 10.1016/S0140-6736(08)61341-0.Bercovich D Ganmore I Scott LM Wainreb G Birger Y Elimelech A et al Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome Lancet 2008372 9648 1484 92 10.1016/S0140-6736(08)61341-0Open DOISearch in Google Scholar

20Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):930–2. doi: 10.1111/j.1365-2141.2008.07552.x.Gaikwad A Rye CL Devidas M Heerema NA Carroll AJ Izraeli S et al Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia Br J Haematol 2009144 6 930 2 10.1111/j.1365-2141.2008.07552.xOpen DOISearch in Google Scholar

21Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646–8. doi: 10.1182/blood-2008-08-170928.Kearney L Gonzalez De Castro D Yeung J Procter J Horsley SW Eguchi-Ishimae M et al Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia Blood 2009113 3 646 8 10.1182/blood-2008-08-170928Open DOISearch in Google Scholar

22Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med. 2010;14(3):504– 27. doi: 10.1111/j.1582-4934.2010.01018.x.Haan C Behrmann I Haan S Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases J Cell Mol Med 201014 3 504– 27 10.1111/j.1582-4934.2010.01018.xOpen DOISearch in Google Scholar

23Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f.Miettinen M McCue PA Sarlomo-Rikala M Rys J Czapiewski P Wazny K et al GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors Am J Surg Pathol 201438 1 13 22 10.1097/PAS.0b013e3182a0218fOpen DOISearch in Google Scholar

24Varsome, The Human Genomics Community; GATA3 c.778+1123T>C SNV | hg38 (varsome.com); GATA3(NM_001002295.2):c.779-1748C>A SNV | hg38 (varsome.com); PIP4K2A c.678+761C>G SNV | hg38 (varsome.com)Varsome, The Human Genomics Community; GATA3 c.778+1123T>C SNV | hg38 (varsome.com); GATA3(NM_001002295.2):c.779-1748C>A SNV | hg38 (varsome.com); PIP4K2A c.678+761C>G SNV | hg38 (varsome.com)Search in Google Scholar

25Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688–98. doi: 10.1182/blood-2009-03-208397.Russell LJ Capasso M Vater I Akasaka T Bernard OA Calasanz MJ et al Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia Blood 2009114 13 2688 98 10.1182/blood-2009-03-208397Open DOISearch in Google Scholar

26Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010;107(1):252–7. doi: 10.1073/pnas.0911726107.Yoda A Yoda Y Chiaretti S Bar-Natan M Mani K Rodig SJ et al Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia Proc Natl Acad Sci U S A 2010107 1 252 7 10.1073/pnas.0911726107Open DOISearch in Google Scholar

27Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7 20. doi: 10.1002/0471142905.hg0720s76.Adzhubei I Jordan DM Sunyaev SR Predicting functional effect of human missense mutations using PolyPhen-2 Curr Protoc Hum Genet 2013 Chapter 7:Unit7 20. 10.1002/0471142905.hg0720s76Open DOISearch in Google Scholar

28Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, et al. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proc Natl Acad Sci U S A. 2017;114(20):E4030-E4039. doi: 10.1073/pnas.1702489114.Schwartzman O Savino AM Gombert M Palmi C Cario G Schrappe M et al Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome Proc Natl Acad Sci U S A 2017114 20 E4030 E4039 10.1073/pnas.1702489114Open DOISearch in Google Scholar

29Pieper K, Grimbacher B, Eibel H. B-Cell development and differentiation. J Allergy Clin Immunol. 2013;131(4):959-71. doi: 10.1016/j.jaci.2013.01.046.Pieper K Grimbacher B Eibel H B-Cell development and differentiation J Allergy Clin Immunol 2013131 4 959 71 10.1016/j.jaci.2013.01.046Open DOISearch in Google Scholar

30Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226-1231. doi: 10.1038/ng.2754.Shah S Schrader KA Waanders E Timms AE Vijai J Miething C et al A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia Nat Genet 2013451226 1231 10.1038/ng.2754Open DOISearch in Google Scholar

31Auer F, Ruschendorf F, Gombert M, Husemann P. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A. Leukemia. 2014;28:1136-1138. doi: 10.1038/leu.2013.363.Auer F Ruschendorf F Gombert M Husemann P Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A Leukemia 2014281136 1138 10.1038/leu.2013.363Open DOISearch in Google Scholar

32Winer P, Muskens IS, Walsh KM, Vora A, Moorman AV, Wiemels JL, et al. Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia. Blood Adv. 2020;4(4):672-675. doi: 10.1182/bloodadvances.2019001216.Winer P Muskens IS Walsh KM Vora A Moorman AV Wiemels JL et al Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia Blood Adv 20204 4 672 675 10.1182/bloodadvances.2019001216Open DOISearch in Google Scholar

33Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021.Churchman ML Qian M Te Kronnie G Zhang R Yang W Zhang H et al Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia Cancer Cell 201833 5 937 948 e8. 10.1016/j.ccell.2018.03.021Open DOISearch in Google Scholar

34Kuehn HS, Boisson B, Cunningham-Rundles C, Reichenbach J. Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043. doi: 10.1056/NEJMoa1512234.Kuehn HS Boisson B Cunningham-Rundles C Reichenbach J Loss of B Cells in Patients with Heterozygous Mutations in IKAROS N Engl J Med 2016374 11 1032 1043 10.1056/NEJMoa1512234Open DOISearch in Google Scholar

35Mullighan, CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–480. doi: 10.1056/NEJMoa0808253.Mullighan CG Su X Zhang J Radtke I Phillips LA Miller CB et al Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia N Engl J Med 2009360470 480 10.1056/NEJMoa0808253Open DOISearch in Google Scholar

36Mullighan, CG, Goorha S, Radtke I, Miller BC, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764. doi: 10.1038/nature05690.Mullighan CG Goorha S Radtke I Miller BC Coustan-Smith E Dalton JD et al Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia Nature 2007446758 764 10.1038/nature05690Open DOISearch in Google Scholar

37Sherborne AL, Hosking F, Prasad BR, Kumar R, Koehler R, Vijayakrishnan J, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010;42(6):492–494. doi: 10.1038/ng.585.Sherborne AL Hosking F Prasad BR Kumar R Koehler R Vijayakrishnan J et al Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk Nat Genet 201042 6 492 494 10.1038/ng.585Open DOISearch in Google Scholar

38Yoshino H, Nishiyama Y, Kamma H, Chiba T. Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood. Int J Hematol. 2020;112(2):217-222. doi: 10.1007/s12185-020-02885-y.Yoshino H Nishiyama Y Kamma H Chiba T Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood Int J Hematol 2020112 2 217 222 10.1007/s12185-020-02885-yOpen DOISearch in Google Scholar

39Poggi M, Canault M, Favier M, Turro E. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102(2):282-294. doi: 10.3324/haematol.2016.147694.Poggi M Canault M Favier M Turro E Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors Haematologica 2017102 2 282 294 10.3324/haematol.2016.147694Open DOISearch in Google Scholar

40Karastaneva A, Nebral K, Schlagenhauf A, Baschin M. Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor. J Med Genet. 2020;57(6):427-433. doi: 10.1136/jmedgenet-2019-106339.Karastaneva A Nebral K Schlagenhauf A Baschin M Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor J Med Genet 202057 6 427 433 10.1136/jmedgenet-2019-106339Open DOISearch in Google Scholar

41Liao W, Liu Y. Treatment outcomes in children with acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(29):e21015. doi: 10.1097/MD.0000000000021015.Liao W Liu Y Treatment outcomes in children with acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis Medicine (Baltimore) 202099 29 e21015 10.1097/MD.0000000000021015Open DOISearch in Google Scholar

42Bohnstedt C, Levinsen M, Rosthøj S, Zeller B, Taskinen M, Hafsteinsdottir S, et al. Physicians compliance during maintenance therapy in children with Down syndrome and acutelymphoblastic leukemia. Leukemia. 2013;27:866–70. doi: 10.1038/leu.2012.325.Bohnstedt C Levinsen M Rosthøj S Zeller B Taskinen M Hafsteinsdottir S et al Physicians compliance during maintenance therapy in children with Down syndrome and acutelymphoblastic leukemia Leukemia 201327866 70 10.1038/leu.2012.325Open DOISearch in Google Scholar

43Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7. doi: 10.1182/blood-2013-06-509463.Buitenkamp TD Izraeli S Zimmermann M Forestier E Heerema NA van den Heuvel-Eibrink MM et al Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group Blood 201412370 7 10.1182/blood-2013-06-509463Open DOISearch in Google Scholar

44Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE, et al. Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321–5. doi: 10.1136/adc.85.4.321.Chessells JM Harrison G Richards SM Bailey CC Hill FG Gibson BE et al Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment Arch Dis Child 200185321 5 10.1136/adc.85.4.321Open DOISearch in Google Scholar

45Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, et al. Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt- Münster Group. Leukemia. 1998;12:645–51. doi: 10.1038/sj.leu.2400989.Dördelmann M Schrappe M Reiter A Zimmermann M Graf N Schott G et al Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials Berlin-Frankfurt- Münster Group. Leukemia 199812645 51 10.1038/sj.leu.2400989Open DOISearch in Google Scholar

46Matloub Y, Rabin KR, Ji L, Devidas M, Hitzler J, Xu X, et al. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group. Blood Adv. 2019;3:1647–56. doi: 10.1182/bloodadvances.2019032094.Matloub Y Rabin KR Ji L Devidas M Hitzler J Xu X et al Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group Blood Adv 201931647 56 10.1182/bloodadvances.2019032094Open DOISearch in Google Scholar

47Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2005;106:4043–9. doi: 10.1182/blood-2003-10-3446.Whitlock JA Sather HN Gaynon P Robison LL Wells RJ Trigg M et al Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study Blood 20051064043 9 10.1182/blood-2003-10-3446Open DOISearch in Google Scholar

48Zipursky A. Susceptibility to leukemia and resistance to solid tumors in Down syndrome. Pediatric Research. 2000; 47(6): 704. doi: 10.1203/00006450-200006000-00002.Zipursky A Susceptibility to leukemia and resistance to solid tumors in Down syndrome Pediatric Research 2000 47 6 704 10.1203/00006450-200006000-00002Open DOISearch in Google Scholar

49Chiang JC, Jiang J, Newburger PE, Lawrence JB. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro. Nat Commun. 2018; 9(1): 5180. doi: 10.1038/s41467-018-07630-y.Chiang JC Jiang J Newburger PE Lawrence JB Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro Nat Commun 2018 9 1 5180 10.1038/s41467-018-07630-yOpen DOISearch in Google Scholar

50Laurent AP, Kotecha RS and Malinge S. Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome. Leukemia. 2020;34:1984–1999. doi: 10.1038/s41375-020-0854-5.Laurent AP Kotecha RS and Malinge S Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome Leukemia 2020341984 1999 10.1038/s41375-020-0854-5Open DOISearch in Google Scholar

51Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47:672–676. doi: 10.1038/ng.3301.Paulsson K Lilljebjörn H Biloglav A Olsson L Rissler M Castor A et al The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia Nat Genet 201547672 676 10.1038/ng.3301Open DOISearch in Google Scholar

52Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;137–145. doi: 10.1182/asheducation-2018.1.137.Roberts KG Genetics and prognosis of ALL in children vs adults Hematology Am Soc Hematol Educ Program 2018137–145 10.1182/asheducation-2018.1.137Open DOISearch in Google Scholar

53Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–112. doi: 10.1038/nm.4439.Bolouri H Farrar JE Triche T Jr Ries RE Lim EL Alonzo TA et al The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions Nat Med 201824103 112 10.1038/nm.4439Open DOISearch in Google Scholar

54Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun. 2014;5:4654. doi: 10.1038/ncomms5654.Nikolaev SI Garieri M Santoni F Falconnet E Ribaux P Guipponi M et al Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations Nat Commun 201454654 10.1038/ncomms5654Open DOISearch in Google Scholar

55Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–1299. doi: 10.1038/ng.2759.Yoshida K Toki T Okuno Y Kanezaki R Shiraishi Y Sato-Otsubo A et al The landscape of somatic mutations in Down syndrome-related myeloid disorders Nat Genet 2013451293 1299 10.1038/ng.2759Open DOISearch in Google Scholar

56de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017;49:451–456. doi: 10.1038/ng.3772.de Rooij JD Branstetter C Ma J Li Y Walsh MP Cheng J et al Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes Nat Genet 201749451 456 10.1038/ng.3772Open DOISearch in Google Scholar

57Kroll M, Kaupat-Bleckmann K, Mörickel A, Altenl J, Schewel DM, Stanullal M, Zimmermann M, Schrappe M, Cario G. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. Haematologica. 2020;105(4):1013-1020. doi: 10.3324/haematol.2019.224774.Kroll M Kaupat-Bleckmann K Mörickel A Altenl J Schewel DM Stanullal M Zimmermann M Schrappe M Cario G Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen Haematologica 2020105 4 1013 1020 10.3324/haematol.2019.224774Open DOISearch in Google Scholar